Liquidia Technologies Inc (LQDA) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Total Revenue Chart for Liquidia Technologies Inc
Liquidia Technologies Inc (LQDA) revenue for FY2025 was USD 158.3M, a 1031.2% change from FY2024. Liquidia Technologies Inc's revenue grew from USD 13.2M in 2016 to USD 158.3M in 2025 (1097.9% over 9 years). Earnings per share moved from USD -3.13 in 2016 to USD -0.67 in 2022. Revenue compound annual growth rate: 5-year CAGR of 192.5%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $3.82B
- Implied Share Price
- $42.65
- Enterprise Value
- $5.97B
- Revenue (TTM)
- $450.91M
- EBITDA
- $169.77M
- Profit Margin
- 30.74%
- Trailing P/E
- 30.68
- Forward P/E
- 10.58
- Price/Book (MRQ)
- 31.12
- Price/Sales (TTM)
- 8.47
- EV/EBITDA
- 33.58
- EV/Revenue
- 13.24
- Dividend Yield
- —
- Book Value
- $2.19
- Free Cash Flow (FY2025)
- -$40.02M
- Free Cash Flow Yield
- -1.05%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.